Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants.

Additional Information
Market: TSXV
Sector: Pharmaceuticals
EPIC: MDG